Last week our CSO Lars Johansson was invited to participate in the Metabolic multi Organ Science Accelerating Innovation in Clinical trials (MOSAIC) forum. The meeting took place in Washington D.C. on October 19-20. Lars participated as a panellist to give an industry viewpoint on the session “Non-invasive liver endpoints in non-liver trials” (Thursday Oct 19th @ 16.30-17.30 EDT), including the following presentations:
- Which future CVD and CKD trials should be enriched with liver endpoints? Harriette Van Spall (Hamilton, CAN)
- What liver biomarker substudies to recommend in CV trials. Arun Sanyal (Richmond, VA, USA)
- What liver imaging substudies to recommend in CV trials. Mazen Noureddin (Los Angeles, CA, USA)
Lars highlighted what imaging can do beyond the heart, liver, and kidney and the importance of investigating whole-body effects of new pharmacotherapies. He gave some examples of how imaging can be used to assess muscle composition and function, as well as for looking more closely at what is happening in the brain, which generated interest for further discussion.
MOSAIC is a global NASH trialist forum that brings together cardiology, endocrinology, and hepatology clinical trialists with industry, regulatory experts, payers, patient representatives and other stakeholders to discuss metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH) diagnosis and management.